Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.3% – Should You Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE) rose 5.3% during trading on Tuesday . The stock traded as high as $20.54 and last traded at $20.18. Approximately 20,155 shares traded hands during trading, a decline of 90% from the average daily volume of 200,547 shares. The stock had previously closed at $19.17.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Pulse Biosciences Stock Performance

The company’s 50 day moving average price is $17.74 and its two-hundred day moving average price is $16.50.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the prior year, the firm posted ($0.19) earnings per share.

Insider Activity

In other news, Director Robert W. Duggan acquired 56,054 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The stock was purchased at an average cost of $17.35 per share, with a total value of $972,536.90. Following the completion of the purchase, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 71.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences in the first quarter valued at about $88,000. Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences during the first quarter worth about $109,000. Bank of New York Mellon Corp raised its stake in Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after purchasing an additional 9,639 shares during the period. Rhumbline Advisers lifted its holdings in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after purchasing an additional 1,608 shares in the last quarter. Finally, Quest Partners LLC bought a new position in Pulse Biosciences in the 2nd quarter worth approximately $91,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.